0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Rare Biomarkers Market Research Report 2026
Published Date: 2026-04-10
|
Report Code: QYRE-Auto-22A16952
Home | Market Reports
Global Rare Biomarkers Market Research Report 2024
BUY CHAPTERS

Global Rare Biomarkers Market Research Report 2026

Code: QYRE-Auto-22A16952
Report
2026-04-10
Pages:140
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Rare Biomarkers Market

The global Rare Biomarkers market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The North American market for Rare Biomarkers is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Rare Biomarkers is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Rare Biomarkers in Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Rare Biomarkers include Roche, Thermo Fisher Scientific, Abbott, Qiagen, PerkinElmer, Merck KGaA, Bio-Rad Laboratories, Enzo Biochem, Charles River Laboratories International, Eurofins Scientific, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Rare Biomarkers market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rare Biomarkers. The Rare Biomarkers market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Rare Biomarkers market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Rare Biomarkers manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Rare Biomarkers Market Report

Report Metric Details
Report Name Rare Biomarkers Market
Segment by Type
  • Circulating Cell Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Extracellular Vesicles
  • Circulating Cell Free RNA (ccfRNA) / miRNA
Segment by Application
  • Diagnostics
  • Drug Development
  • Disease Discovery
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Thermo Fisher Scientific, Abbott, Qiagen, PerkinElmer, Merck KGaA, Bio-Rad Laboratories, Enzo Biochem, Charles River Laboratories International, Eurofins Scientific, Agilent Technologies, Bruker, Siemens Healthineers, Epigenomics, GE HealthCare, Diaceutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Rare Biomarkers companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Rare Biomarkers Market report?

Ans: The main players in the Rare Biomarkers Market are Roche, Thermo Fisher Scientific, Abbott, Qiagen, PerkinElmer, Merck KGaA, Bio-Rad Laboratories, Enzo Biochem, Charles River Laboratories International, Eurofins Scientific, Agilent Technologies, Bruker, Siemens Healthineers, Epigenomics, GE HealthCare, Diaceutics

What are the Application segmentation covered in the Rare Biomarkers Market report?

Ans: The Applications covered in the Rare Biomarkers Market report are Diagnostics, Drug Development, Disease Discovery, Other

What are the Type segmentation covered in the Rare Biomarkers Market report?

Ans: The Types covered in the Rare Biomarkers Market report are Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rare Biomarkers Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Circulating Cell Free DNA (ccfDNA)
1.2.3 Circulating Tumor Cells (CTCs)
1.2.4 Exosomes/Extracellular Vesicles
1.2.5 Circulating Cell Free RNA (ccfRNA) / miRNA
1.3 Market by Application
1.3.1 Global Rare Biomarkers Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Diagnostics
1.3.3 Drug Development
1.3.4 Disease Discovery
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rare Biomarkers Market Perspective (2021–2032)
2.2 Global Rare Biomarkers Growth Trends by Region
2.2.1 Global Rare Biomarkers Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Rare Biomarkers Historic Market Size by Region (2021–2026)
2.2.3 Rare Biomarkers Forecasted Market Size by Region (2027–2032)
2.3 Rare Biomarkers Market Dynamics
2.3.1 Rare Biomarkers Industry Trends
2.3.2 Rare Biomarkers Market Drivers
2.3.3 Rare Biomarkers Market Challenges
2.3.4 Rare Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rare Biomarkers Players by Revenue
3.1.1 Global Top Rare Biomarkers Players by Revenue (2021–2026)
3.1.2 Global Rare Biomarkers Revenue Market Share by Players (2021–2026)
3.2 Global Top Rare Biomarkers Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Rare Biomarkers Revenue
3.4 Global Rare Biomarkers Market Concentration Ratio
3.4.1 Global Rare Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rare Biomarkers Revenue in 2025
3.5 Global Key Players of Rare Biomarkers Head Offices and Areas Served
3.6 Global Key Players of Rare Biomarkers, Products and Applications
3.7 Global Key Players of Rare Biomarkers, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Rare Biomarkers Breakdown Data by Type
4.1 Global Rare Biomarkers Historic Market Size by Type (2021–2026)
4.2 Global Rare Biomarkers Forecasted Market Size by Type (2027–2032)
5 Rare Biomarkers Breakdown Data by Application
5.1 Global Rare Biomarkers Historic Market Size by Application (2021–2026)
5.2 Global Rare Biomarkers Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Rare Biomarkers Market Size (2021–2032)
6.2 North America Rare Biomarkers Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Rare Biomarkers Market Size by Country (2021–2026)
6.4 North America Rare Biomarkers Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rare Biomarkers Market Size (2021–2032)
7.2 Europe Rare Biomarkers Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Rare Biomarkers Market Size by Country (2021–2026)
7.4 Europe Rare Biomarkers Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Rare Biomarkers Market Size (2021–2032)
8.2 Asia-Pacific Rare Biomarkers Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Rare Biomarkers Market Size by Region (2021–2026)
8.4 Asia-Pacific Rare Biomarkers Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Rare Biomarkers Market Size (2021–2032)
9.2 Latin America Rare Biomarkers Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Rare Biomarkers Market Size by Country (2021–2026)
9.4 Latin America Rare Biomarkers Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rare Biomarkers Market Size (2021–2032)
10.2 Middle East & Africa Rare Biomarkers Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Rare Biomarkers Market Size by Country (2021–2026)
10.4 Middle East & Africa Rare Biomarkers Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Rare Biomarkers Introduction
11.1.4 Roche Revenue in Rare Biomarkers Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Details
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Rare Biomarkers Introduction
11.2.4 Thermo Fisher Scientific Revenue in Rare Biomarkers Business (2021–2026)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Abbott
11.3.1 Abbott Company Details
11.3.2 Abbott Business Overview
11.3.3 Abbott Rare Biomarkers Introduction
11.3.4 Abbott Revenue in Rare Biomarkers Business (2021–2026)
11.3.5 Abbott Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Details
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Rare Biomarkers Introduction
11.4.4 Qiagen Revenue in Rare Biomarkers Business (2021–2026)
11.4.5 Qiagen Recent Development
11.5 PerkinElmer
11.5.1 PerkinElmer Company Details
11.5.2 PerkinElmer Business Overview
11.5.3 PerkinElmer Rare Biomarkers Introduction
11.5.4 PerkinElmer Revenue in Rare Biomarkers Business (2021–2026)
11.5.5 PerkinElmer Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Rare Biomarkers Introduction
11.6.4 Merck KGaA Revenue in Rare Biomarkers Business (2021–2026)
11.6.5 Merck KGaA Recent Development
11.7 Bio-Rad Laboratories
11.7.1 Bio-Rad Laboratories Company Details
11.7.2 Bio-Rad Laboratories Business Overview
11.7.3 Bio-Rad Laboratories Rare Biomarkers Introduction
11.7.4 Bio-Rad Laboratories Revenue in Rare Biomarkers Business (2021–2026)
11.7.5 Bio-Rad Laboratories Recent Development
11.8 Enzo Biochem
11.8.1 Enzo Biochem Company Details
11.8.2 Enzo Biochem Business Overview
11.8.3 Enzo Biochem Rare Biomarkers Introduction
11.8.4 Enzo Biochem Revenue in Rare Biomarkers Business (2021–2026)
11.8.5 Enzo Biochem Recent Development
11.9 Charles River Laboratories International
11.9.1 Charles River Laboratories International Company Details
11.9.2 Charles River Laboratories International Business Overview
11.9.3 Charles River Laboratories International Rare Biomarkers Introduction
11.9.4 Charles River Laboratories International Revenue in Rare Biomarkers Business (2021–2026)
11.9.5 Charles River Laboratories International Recent Development
11.10 Eurofins Scientific
11.10.1 Eurofins Scientific Company Details
11.10.2 Eurofins Scientific Business Overview
11.10.3 Eurofins Scientific Rare Biomarkers Introduction
11.10.4 Eurofins Scientific Revenue in Rare Biomarkers Business (2021–2026)
11.10.5 Eurofins Scientific Recent Development
11.11 Agilent Technologies
11.11.1 Agilent Technologies Company Details
11.11.2 Agilent Technologies Business Overview
11.11.3 Agilent Technologies Rare Biomarkers Introduction
11.11.4 Agilent Technologies Revenue in Rare Biomarkers Business (2021–2026)
11.11.5 Agilent Technologies Recent Development
11.12 Bruker
11.12.1 Bruker Company Details
11.12.2 Bruker Business Overview
11.12.3 Bruker Rare Biomarkers Introduction
11.12.4 Bruker Revenue in Rare Biomarkers Business (2021–2026)
11.12.5 Bruker Recent Development
11.13 Siemens Healthineers
11.13.1 Siemens Healthineers Company Details
11.13.2 Siemens Healthineers Business Overview
11.13.3 Siemens Healthineers Rare Biomarkers Introduction
11.13.4 Siemens Healthineers Revenue in Rare Biomarkers Business (2021–2026)
11.13.5 Siemens Healthineers Recent Development
11.14 Epigenomics
11.14.1 Epigenomics Company Details
11.14.2 Epigenomics Business Overview
11.14.3 Epigenomics Rare Biomarkers Introduction
11.14.4 Epigenomics Revenue in Rare Biomarkers Business (2021–2026)
11.14.5 Epigenomics Recent Development
11.15 GE HealthCare
11.15.1 GE HealthCare Company Details
11.15.2 GE HealthCare Business Overview
11.15.3 GE HealthCare Rare Biomarkers Introduction
11.15.4 GE HealthCare Revenue in Rare Biomarkers Business (2021–2026)
11.15.5 GE HealthCare Recent Development
11.16 Diaceutics
11.16.1 Diaceutics Company Details
11.16.2 Diaceutics Business Overview
11.16.3 Diaceutics Rare Biomarkers Introduction
11.16.4 Diaceutics Revenue in Rare Biomarkers Business (2021–2026)
11.16.5 Diaceutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Rare Biomarkers Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Circulating Cell Free DNA (ccfDNA)
 Table 3. Key Players of Circulating Tumor Cells (CTCs)
 Table 4. Key Players of Exosomes/Extracellular Vesicles
 Table 5. Key Players of Circulating Cell Free RNA (ccfRNA) / miRNA
 Table 6. Global Rare Biomarkers Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Rare Biomarkers Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 8. Global Rare Biomarkers Market Size by Region (US$ Million), 2021–2026
 Table 9. Global Rare Biomarkers Market Share by Region (2021–2026)
 Table 10. Global Rare Biomarkers Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 11. Global Rare Biomarkers Market Share by Region (2027–2032)
 Table 12. Rare Biomarkers Market Trends
 Table 13. Rare Biomarkers Market Drivers
 Table 14. Rare Biomarkers Market Challenges
 Table 15. Rare Biomarkers Market Restraints
 Table 16. Global Rare Biomarkers Revenue by Players (US$ Million), 2021–2026
 Table 17. Global Rare Biomarkers Market Share by Players (2021–2026)
 Table 18. Global Top Rare Biomarkers Players by Tier (Tier 1, Tier 2, and Tier 3), based on Rare Biomarkers Revenue, 2025
 Table 19. Ranking of Global Top Rare Biomarkers Companies by Revenue (US$ Million) in 2025
 Table 20. Global 5 Largest Players Market Share by Rare Biomarkers Revenue (CR5 and HHI), 2021–2026
 Table 21. Global Key Players of Rare Biomarkers, Headquarters and Area Served
 Table 22. Global Key Players of Rare Biomarkers, Products and Applications
 Table 23. Global Key Players of Rare Biomarkers, Date of General Availability (GA)
 Table 24. Mergers and Acquisitions, Expansion Plans
 Table 25. Global Rare Biomarkers Market Size by Type (US$ Million), 2021–2026
 Table 26. Global Rare Biomarkers Revenue Market Share by Type (2021–2026)
 Table 27. Global Rare Biomarkers Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 28. Global Rare Biomarkers Revenue Market Share by Type (2027–2032)
 Table 29. Global Rare Biomarkers Market Size by Application (US$ Million), 2021–2026
 Table 30. Global Rare Biomarkers Revenue Market Share by Application (2021–2026)
 Table 31. Global Rare Biomarkers Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 32. Global Rare Biomarkers Revenue Market Share by Application (2027–2032)
 Table 33. North America Rare Biomarkers Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 34. North America Rare Biomarkers Market Size by Country (US$ Million), 2021–2026
 Table 35. North America Rare Biomarkers Market Size by Country (US$ Million), 2027–2032
 Table 36. Europe Rare Biomarkers Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 37. Europe Rare Biomarkers Market Size by Country (US$ Million), 2021–2026
 Table 38. Europe Rare Biomarkers Market Size by Country (US$ Million), 2027–2032
 Table 39. Asia-Pacific Rare Biomarkers Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 40. Asia-Pacific Rare Biomarkers Market Size by Region (US$ Million), 2021–2026
 Table 41. Asia-Pacific Rare Biomarkers Market Size by Region (US$ Million), 2027–2032
 Table 42. Latin America Rare Biomarkers Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 43. Latin America Rare Biomarkers Market Size by Country (US$ Million), 2021–2026
 Table 44. Latin America Rare Biomarkers Market Size by Country (US$ Million), 2027–2032
 Table 45. Middle East & Africa Rare Biomarkers Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 46. Middle East & Africa Rare Biomarkers Market Size by Country (US$ Million), 2021–2026
 Table 47. Middle East & Africa Rare Biomarkers Market Size by Country (US$ Million), 2027–2032
 Table 48. Roche Company Details
 Table 49. Roche Business Overview
 Table 50. Roche Rare Biomarkers Product
 Table 51. Roche Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 52. Roche Recent Development
 Table 53. Thermo Fisher Scientific Company Details
 Table 54. Thermo Fisher Scientific Business Overview
 Table 55. Thermo Fisher Scientific Rare Biomarkers Product
 Table 56. Thermo Fisher Scientific Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 57. Thermo Fisher Scientific Recent Development
 Table 58. Abbott Company Details
 Table 59. Abbott Business Overview
 Table 60. Abbott Rare Biomarkers Product
 Table 61. Abbott Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 62. Abbott Recent Development
 Table 63. Qiagen Company Details
 Table 64. Qiagen Business Overview
 Table 65. Qiagen Rare Biomarkers Product
 Table 66. Qiagen Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 67. Qiagen Recent Development
 Table 68. PerkinElmer Company Details
 Table 69. PerkinElmer Business Overview
 Table 70. PerkinElmer Rare Biomarkers Product
 Table 71. PerkinElmer Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 72. PerkinElmer Recent Development
 Table 73. Merck KGaA Company Details
 Table 74. Merck KGaA Business Overview
 Table 75. Merck KGaA Rare Biomarkers Product
 Table 76. Merck KGaA Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 77. Merck KGaA Recent Development
 Table 78. Bio-Rad Laboratories Company Details
 Table 79. Bio-Rad Laboratories Business Overview
 Table 80. Bio-Rad Laboratories Rare Biomarkers Product
 Table 81. Bio-Rad Laboratories Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 82. Bio-Rad Laboratories Recent Development
 Table 83. Enzo Biochem Company Details
 Table 84. Enzo Biochem Business Overview
 Table 85. Enzo Biochem Rare Biomarkers Product
 Table 86. Enzo Biochem Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 87. Enzo Biochem Recent Development
 Table 88. Charles River Laboratories International Company Details
 Table 89. Charles River Laboratories International Business Overview
 Table 90. Charles River Laboratories International Rare Biomarkers Product
 Table 91. Charles River Laboratories International Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 92. Charles River Laboratories International Recent Development
 Table 93. Eurofins Scientific Company Details
 Table 94. Eurofins Scientific Business Overview
 Table 95. Eurofins Scientific Rare Biomarkers Product
 Table 96. Eurofins Scientific Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 97. Eurofins Scientific Recent Development
 Table 98. Agilent Technologies Company Details
 Table 99. Agilent Technologies Business Overview
 Table 100. Agilent Technologies Rare Biomarkers Product
 Table 101. Agilent Technologies Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 102. Agilent Technologies Recent Development
 Table 103. Bruker Company Details
 Table 104. Bruker Business Overview
 Table 105. Bruker Rare Biomarkers Product
 Table 106. Bruker Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 107. Bruker Recent Development
 Table 108. Siemens Healthineers Company Details
 Table 109. Siemens Healthineers Business Overview
 Table 110. Siemens Healthineers Rare Biomarkers Product
 Table 111. Siemens Healthineers Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 112. Siemens Healthineers Recent Development
 Table 113. Epigenomics Company Details
 Table 114. Epigenomics Business Overview
 Table 115. Epigenomics Rare Biomarkers Product
 Table 116. Epigenomics Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 117. Epigenomics Recent Development
 Table 118. GE HealthCare Company Details
 Table 119. GE HealthCare Business Overview
 Table 120. GE HealthCare Rare Biomarkers Product
 Table 121. GE HealthCare Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 122. GE HealthCare Recent Development
 Table 123. Diaceutics Company Details
 Table 124. Diaceutics Business Overview
 Table 125. Diaceutics Rare Biomarkers Product
 Table 126. Diaceutics Revenue in Rare Biomarkers Business (US$ Million), 2021–2026
 Table 127. Diaceutics Recent Development
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Rare Biomarkers Picture
 Figure 2. Global Rare Biomarkers Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Rare Biomarkers Market Share by Type: 2025 vs 2032
 Figure 4. Circulating Cell Free DNA (ccfDNA) Features
 Figure 5. Circulating Tumor Cells (CTCs) Features
 Figure 6. Exosomes/Extracellular Vesicles Features
 Figure 7. Circulating Cell Free RNA (ccfRNA) / miRNA Features
 Figure 8. Global Rare Biomarkers Market Size by Application (US$ Million), 2021–2032
 Figure 9. Global Rare Biomarkers Market Share by Application: 2025 vs 2032
 Figure 10. Diagnostics Case Studies
 Figure 11. Drug Development Case Studies
 Figure 12. Disease Discovery Case Studies
 Figure 13. Other Case Studies
 Figure 14. Rare Biomarkers Report Years Considered
 Figure 15. Global Rare Biomarkers Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 16. Global Rare Biomarkers Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 17. Global Rare Biomarkers Market Share by Region: 2025 vs 2032
 Figure 18. Global Rare Biomarkers Market Share by Players in 2025
 Figure 19. Global Rare Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 20. The Top 10 and 5 Players Market Share by Rare Biomarkers Revenue in 2025
 Figure 21. North America Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. North America Rare Biomarkers Market Share by Country (2021–2032)
 Figure 23. United States Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Canada Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Europe Rare Biomarkers Market Share by Country (2021–2032)
 Figure 27. Germany Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. France Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. U.K. Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Italy Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Russia Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Ireland Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Asia-Pacific Rare Biomarkers Market Share by Region (2021–2032)
 Figure 35. China Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Japan Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. South Korea Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Southeast Asia Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. India Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Australia & New Zealand Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Latin America Rare Biomarkers Market Share by Country (2021–2032)
 Figure 43. Mexico Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Brazil Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Middle East & Africa Rare Biomarkers Market Share by Country (2021–2032)
 Figure 47. Israel Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Saudi Arabia Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. UAE Rare Biomarkers Market Size YoY Growth (US$ Million), 2021–2032
 Figure 50. Roche Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 52. Abbott Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 53. Qiagen Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 54. PerkinElmer Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 55. Merck KGaA Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 56. Bio-Rad Laboratories Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 57. Enzo Biochem Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 58. Charles River Laboratories International Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 59. Eurofins Scientific Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 60. Agilent Technologies Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 61. Bruker Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 62. Siemens Healthineers Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 63. Epigenomics Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 64. GE HealthCare Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 65. Diaceutics Revenue Growth Rate in Rare Biomarkers Business (2021–2026)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona